 |
BioWorld-International-2008-12-24
Biocompatibles in $422M Deal With AstraZeneca in Diabetes
Trophos Receives €7M in Grants, Refocuses Development Efforts
No Abstract
BioWorld International Correspondent
PARIS - Trophos received €7 million (US$9.77 million) in funding for two projects involving the company's lead candidate, TRO19622, one of several cholesterol-oxime-based compounds it is developing for the treatment of neurodegenerative diseases.
Biocompatibles in $422M Deal With AstraZeneca in Diabetes
LONDON - Biocompatibles International plc sealed a deal with AstraZeneca plc worth a potential €302.3 million (US$422.6 million) for a glucagon-like peptide (GLP-1) analogue for treating diabetes and obesity. (BioWorld International)
Norway Biotechs Seek €300M Bailout to Ease Funding Crisis
No Abstract
BioWorld International Correspondent
The Oslo Cancer Cluster, a Norwegian industry and research cluster focused on oncology, is seeking a €300 million (US$418 million) government bailout to help the country's fledgling biotechnology sector to weather the international financial crisis.